

- Malone, Arnold—Cont.**  
 Procedure and Committee business—*Cont.*  
 Witnesses—*Cont.*  
 Inviting—*Cont.*  
 M. (White), 8:29, 31-2
- Manitoba**  
 Cabinet ministers *see* Generic drugs—Banning  
 Federal government/Mackling consultations *re* Bill C-22, 15:92-3;  
 16:13-4  
 Government *see* Committee—Witnesses, Inviting; Witnesses  
*See also* Drug plans; Drugs and pharmaceuticals—Costs/prices,  
 Deterrent fees—Provinces; Health care—Erosion;  
 Physicians/researchers
- Manson, John** (Bio-mega Inc.)  
 Patent Act (amdt.)(Bill C-22), 12:3, 5-16  
 References, background/credentials, 12:13
- Martin, Jean-Claude** (Canadian Hospital Association)  
 Patent Act (amdt.)(Bill C-22), 15:3, 18-30
- McCurdy, Howard** (NDP—Windsor—Walkerville)  
 Brand name drugs, 3:68-70; 6:79  
 Drug plans, 6:80  
 Drugs and pharmaceuticals, 3:68; 6:80-1  
 Harley report, 3:68-9  
 Multinational corporations, 3:68  
 Ontario Drug Benefit Plan, 6:79-80  
 Patent Act (amdt.)(Bill C-22), 3:25-6, 68-70; 4:15, 18-20, 23-31,  
 34-41; 5:5-8; 6:78-81, 83  
 Procedure and Committee business  
 Bills, M. (White), 4:18, 24, 38; 5:6  
 Amdt., 4:31  
 Briefs, 4:18-9, 24, 38-9; 5:6-7  
 Meetings, M. (White), 5:6  
 Members, 4:19  
 Questioning of witnesses, 3:26  
 Witnesses, M. (White), 4:19-20, 23-4, 34-41; 5:5-6  
 Amdt. (Kempling), 4:25-7  
 Amdt., 4:28-31  
 Terry Fox Medical Research Foundation, 3:69-70
- McInnes, Hon. Stewart** *see* Dalhousie University Medical School
- McLeod, Malcolm** (Patent and Trademark Institute)  
 Patent Act (amdt.)(Bill C-22), 6:3, 5-7, 18
- McMaster University Faculty of Health Sciences**  
 Dean's letter *re* Bill C-22, 11:16-7  
 Generic drug policy, 9:41  
 Students, Bill C-22 opposing, Andre letter, etc., 9:41  
*See also* Appendices
- McPherson, Cathy** (Coalition of Provincial Organizations of the  
 Handicapped)  
 Patent Act (amdt.)(Bill C-22), 15:3, 71-6, 78-80
- Medical journals, Canadian**  
 Research standards, criticism, 9:41, 48-9
- Medical Research Council**  
 Budget, federal government capping, 6:34, 43; 7:11; 11:46; 13:25,  
 44; 14:13, 48-51; 15:8, 12-3, 15  
 Canadian Red Cross Society/Roche letter, 13:26  
 Funding, proposals, 11:7; 12:58; 15:49  
 Research, extent, 11:11; 15:12-3
- Medical schools** *see* Universities
- Medicare**  
 Legislation, Bill C-22 eroding, 15:55  
*See also* Drug prescriptions—Growth
- Medicine** *see* Cardiovascular medicine
- Merck Frosst Canada Inc.,** 10:12, 42; 11:7  
 Canadian origin, Montreal, Que., United States take-over, 6:51;  
 11:11  
 Research commitments, 10:13-4
- Mice** *see* University of Western Ontario
- Michaud, Wilfred** (Quebec Federation of Senior Citizens)  
 Patent Act (amdt.)(Bill C-22), 12:3, 16-9, 22-3, 25-6, 28
- Mitchell, R.E.** (Canadian Chamber of Commerce)  
 Patent Act (amdt.)(Bill C-22), 8:3, 19-20, 23-5, 28
- Monopolies**  
 Abuse, Competition Act provisions, 16:69  
 State protection, legitimacy, 6:85  
*See also* Brand name drugs—Industry; Drug patents; Patent Act  
 (amdt.)(Bill C-22)—References
- Montreal Board of Trade**  
 Andre letter, tabling, 10:7  
*See also* Witnesses
- Montreal, Que.** *see* Ayerst Laboratories; Drugs and pharmaceuticals  
 industry; Merck Frosst Canada Inc.; *Rise and Fall of Montreal,*  
*The*
- Mullen, W.** (Federal Superannuates National Association)  
 Patent Act (amdt.)(Bill C-22), 14:3, 54-66
- Mulroney, Right Hon. Brian** *see* Canadian Automobile Workers  
 Union; Drugs and pharmaceuticals industry—Research and  
 development, Gross National Product
- Multinational corporations**  
 Lobby group/voice, lacking, 12:76  
 Research expense to sales ratio, 3:68  
*Stop Multinationals Monopolizing Medicine*, article *see* Drugs and  
 pharmaceuticals—Costs/prices  
*See also* Brand name drugs; Drug plans—Generic; Drug Prices  
 Review Board—Regulatory powers, Regulatory capture; Drugs  
 and pharmaceuticals industry—Research and development
- Multiple sclerosis**  
 Research, need, 8:7  
 Victims, drug costs/coverage, etc., 8:8, 11-4, 24
- Multiple Sclerosis Society of Ottawa-Carleton**  
 Background, 8:13  
 Drug use survey, 8:6, 9-10  
 National organization, Bill C-22 position, 8:16  
*See also* Witnesses
- National Action Committee on the Status of Women** *see* Witnesses
- National Anti-Poverty Organization**  
 Background, 12:55  
*See also* Witnesses
- National Biotechnology Advisory Committee**  
 Background, 12:45  
*See also* Witnesses
- National Federation of Nurses' Unions**  
 Background, Andre/provinces consultations *re* Bill C-22, 9:29-30,  
 36-8